For decades, RSV prevention relied on monoclonal antibodies for high-risk infants, with no approved vaccines available. The approval of RSV vaccines for older adults and maternal immunization represents a major breakthrough, transforming prevention and driving growth in the Respiratory Syncytial Virus (RSV) Therapeutics Market.

Vaccines for Older Adults

RSV vaccines for older adults, such as Arexvy (GSK) and Abrysvo (Pfizer), have been approved in multiple countries. These vaccines have demonstrated efficacy in preventing lower respiratory tract disease caused by RSV in adults aged 60 and older. The availability of these vaccines is driving demand and expanding the market.

Maternal Immunization

Maternal immunization with RSV vaccines, such as Abrysvo, protects infants from RSV during the first months of life. This approach leverages the transfer of maternal antibodies to the fetus, providing passive immunity. The approval of maternal RSV vaccines represents a significant advancement in protecting vulnerable infants, driving market growth.

People Also Ask

What RSV vaccines are available?
RSV vaccines include Arexvy (GSK) and Abrysvo (Pfizer) for older adults, and Abrysvo for maternal immunization.

How do RSV vaccines work?
RSV vaccines stimulate the immune system to produce antibodies against RSV, preventing or reducing the severity of infection.

As RSV vaccine technology advances and coverage expands, the RSV therapeutics market will continue to grow, driven by the demand for prevention.

Tags: #RSVVaccines #Prevention #MaternalImmunization #OlderAdults #RSVPrevention